Ongoing Psychedelics Research Could Yield Novel Treatments for Mental Disorders

Data from the National Alliance of Mental Health suggests that one in five adults will suffer from a mental health condition in their lifetime. Traditional treatments cause various side effects and can take time to work, which has prompted researchers to seek alternative treatment options for these conditions.

Chang Lu, a researcher from Virginia Tech, has been conducting research on psychedelics that could be used in the treatment of different mental health conditions. Lu, who is a Fred W. Bull Professor of Chemical Engineering, is using a process developed in his laboratory to help collaborators at Virginia Commonwealth University carry out research on the epigenomic effects of psychedelic substances. Their study’s findings may give researchers insight into how substances such as LSD, mescaline and psilocybin can help manage symptoms of PTSD, depression, anxiety and addiction. It has been observed that the drugs last longer and work faster than current drugs, all while causing fewer side effects.

The process, known as genomic analysis, will enable researchers to use small samples of tissue and draw relevant conclusions from those samples. Unlike other approaches that require larger sample sizes, this particular process allows studies to use a small sample size extracted from certain regions of a mouse’s brain.

For their study, the researchers used a drug similar to LSD known as DOI, which they administered to mice which had been trained to fear particular triggers. They then analyzed brain samples for changes in gene expression and the epigenome, discovering that epigenomic variations lasted longer in comparison to gene expression changes, which increased the likelihood of them linking to the long term effects of psychedelics.

The researchers also found that after they had administered one dose of DOI, mice that had reacted to triggers didn’t respond to those triggers anxiously anymore. In addition, the brains of the mice also demonstrated effects, even after the drug could no longer be detected in their tissues.

The researchers believe that observing the effects of psychedelic substances on brain tissues is important because it allows them to learn why the substances work in a certain way.

Lu states that observing molecular changes in animal models, such as mice, will allow researchers to understand the biological processes at work. The researchers note that while the brains of mice are different from the brains of humans, the similarities are enough to make well-founded comparisons between the two.

The study’s findings were reported in the “Cell Reports” journal.

Many companies are also conducting R&D activities aimed at commercializing psychedelic treatments for mental health conditions and other indications. Those companies include Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF).

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.